In 50 Words: Singapore-based Mirxes eyes Hong Kong IPO at $600m valuation

NewsPremium

👩‍🍳 How we use AI at Tech in Asia, thoughtfully and responsibly.
🧔‍♂️ A friendly human may check it before it goes live. More news here

In 50 Words: Singapore-based Mirxes eyes Hong Kong IPO at $600m valuation

Add TIA as a preferred source

Singaporean firm Mirxes is seeking approval for an initial public offering (IPO) on the Hong Kong stock exchange, paving the way for it to be the first company outside China and Hong Kong to be granted a biotech IPO on the exchange.

The cancer diagnostics company recently raised US$50 million, valuing the company at around US$600 million.

Stay ahead in Asia’s tech landscape

You've reached your 2 free content limit for the month. Sign up for free to read the full story.

🏄 For casual readers / 👶 Free

Basic

US$0

Free forever

Get instant access to this article and more every month

0 premium content

Unlimited news briefs

5 articles

Ad-free reading experience

Just US$0 per day

⌛Sign up in 20s. No payment details needed.

📖 For learners / 👍 Starter

Lite

US$4.92/month

Billed annually at US$59/year

Get instant access to this article and more every month

4 premium content

Unlimited news briefs & articles

Ad-free reading experience

Just US$0.17 per day

Cancel anytime

Our subscriber community includes professionals from these companies:

Stay ahead in Asia’s tech landscape

Stay updated on the go with our mobile app.